Targeting specific RNA molecules in immune cells to treat brain tumors
Official title: Macrophage-targeted lncRNA-regulating nanoparticles for glioblastoma treatment
Funded at Emory University · NIH-10932887 · Data updated 2026-11-12
This study is looking at how specific molecules in immune cells might help brain cancer grow, and it aims to create tiny particles that can target these molecules to slow down the cancer and help patients feel better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 21, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $379,513 |
| NIH project number | 5R01NS132725-02 |
| Project ID | NIH-10932887 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who may benefit from novel therapeutic approaches targeting immune suppression.
✕Less likely to help
Patients with other types of brain tumors or those who do not have glioblastoma may not receive benefits from this research.
What this research studies
This research investigates how certain long non-coding RNAs (lncRNAs) in immune cells called macrophages contribute to the progression of glioblastoma, a type of brain cancer. The team aims to develop nanoparticles that can specifically target these lncRNAs to inhibit tumor growth and improve patient outcomes. By analyzing RNA from both tumor tissue and blood samples, they will identify which lncRNAs are involved in immune suppression related to glioblastoma. This approach could lead to new immune-based therapies for patients with this aggressive cancer.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have gone: While targeting lncRNAs with nanoparticles is a relatively novel approach, there is emerging evidence suggesting that similar strategies have shown promise in other cancer types.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Nduom, Edjah — Emory University
- Study coordinator: Nduom, Edjah
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.